You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

CLINICAL TRIALS PROFILE FOR ISOFLURANE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for ISOFLURANE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT01691690 ↗ Analgesic Effect of IV Acetaminophen in Tonsillectomies Completed Nationwide Children's Hospital Phase 2 2012-10-01 Acetaminophen (paracetamol) is a first-line antipyretic and analgesic for mild and moderate pain for pediatric patients. Its common use (particularly in oral form) is underscored by its wide therapeutic window, safety profile, over the counter accessibility, lack of adverse systemic effects (as compared with NSAIDS and opioids) when given in appropriate doses. Although the exact anti-nociceptive mechanisms of acetaminophen continue to be elucidated, these mechanisms appear to be multi-factorial and include central inhibition of the cyclo-oxygenase (COX) enzyme leading to decreased production of prostaglandins from arachidonic acid, interference with serotonergic descending pain pathways, indirect activation of cannabinoid 1 (CB1) receptors and inhibition of nitric oxide pathways through N-methyl-D-aspartate (NMDA) or substance P. Of the above mechanisms, the most commonly known is that of central inhibition of COX enzymes by which the decreased production of prostaglandins diminish the release of excitatory transmitters of substance P and glutamate which are both involved in nociceptive transmission (Anderson, 2008; Smith, 2011). To date, several studies have shown acetaminophen's opioid sparing effect in the pediatric population when given by the rectal or intravenous routes (Korpela et al, 1999; Dashti et al, 2009; Hong et al, 2010).
New Indication NCT05708742 ↗ Erector Spinae Plane Block and Ankle and Foot Surgery Recruiting Fayoum University Hospital N/A 2023-01-01 Regional anesthesia is commonly used in orthopedic and surgical procedures in ankle and foot surgery to manage pain. The ultrasound-guided nerve block is a safe and effective regional anesthesia technique that provides effective pain management, decreasing opioid consumption. Postoperative pain management may be challenging and requires a multimodal approach. Regional anesthesia techniques in the pediatric ankle and foot surgery population are frequently used in postoperative pain management due to ultrasonography's increased experience and accessibility. Erector spinae plane block (ESP) is a relatively new regional anesthesia technique that provides analgesia covering spinal nerves' dorsal and ventral rami. There are few cases reports in the literature on the use of ESP block for lower limb surgery, for which it has a promising potential for future indication. The erector spinae plane block is a safe and effective regional anesthesia technique, which has earned new indications perioperatively since its description.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for ISOFLURANE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000251 ↗ Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide - 3 Completed National Institute on Drug Abuse (NIDA) Phase 2 1994-04-01 The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. To evaluate the acute and residual effects of subanesthetic concentrations of isoflurane/nitrous oxide combinations in healthy volunteers.
NCT00000251 ↗ Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide - 3 Completed University of Chicago Phase 2 1994-04-01 The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. To evaluate the acute and residual effects of subanesthetic concentrations of isoflurane/nitrous oxide combinations in healthy volunteers.
NCT00000254 ↗ Isoflurane at Subanesthetic Concentrations - 6 Completed National Institute on Drug Abuse (NIDA) Phase 2 1995-01-01 The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. To test the hypothesis that isoflurane at subanesthetic concentrations does not reduce cold-water immersion pain in healthy volunteers.
NCT00000254 ↗ Isoflurane at Subanesthetic Concentrations - 6 Completed University of Chicago Phase 2 1995-01-01 The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. To test the hypothesis that isoflurane at subanesthetic concentrations does not reduce cold-water immersion pain in healthy volunteers.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ISOFLURANE

Condition Name

Condition Name for ISOFLURANE
Intervention Trials
Anesthesia 17
Pain, Postoperative 13
Postoperative Pain 13
Dexmedetomidine 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ISOFLURANE
Intervention Trials
Pain, Postoperative 40
Hypotension 10
Delirium 9
Heart Diseases 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ISOFLURANE

Trials by Country

Trials by Country for ISOFLURANE
Location Trials
Egypt 102
China 54
United States 37
Pakistan 15
Brazil 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ISOFLURANE
Location Trials
Ohio 5
Texas 4
North Carolina 4
New York 4
Illinois 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ISOFLURANE

Clinical Trial Phase

Clinical Trial Phase for ISOFLURANE
Clinical Trial Phase Trials
PHASE4 5
PHASE3 7
PHASE2 10
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ISOFLURANE
Clinical Trial Phase Trials
Completed 134
Recruiting 72
Unknown status 28
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ISOFLURANE

Sponsor Name

Sponsor Name for ISOFLURANE
Sponsor Trials
Ain Shams University 21
Kasr El Aini Hospital 17
Fayoum University Hospital 15
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ISOFLURANE
Sponsor Trials
Other 365
Industry 8
OTHER_GOV 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Isoflurane

Last updated: January 27, 2026


Executive Summary

Isoflurane, a volatile anesthetic agent primarily used for induction and maintenance of general anesthesia, is experiencing renewed interest driven by ongoing clinical trials, regulatory considerations, and market trends in anesthesia and critical care. This report offers a comprehensive update on the current status of clinical research, an analysis of the global market landscape, and future projections based on regulatory developments, technological innovations, and healthcare industry dynamics.


I. Clinical Trials Update for Isoflurane

Current Status and Ongoing Trials

Isoflurane's clinical development primarily focuses on its applications beyond traditional anesthesia—specifically, potential neuroprotective roles, efficacy in pediatric populations, and use in intensive care settings.

Parameter Details
Number of active trials 18 (as of Q1 2023, ClinicalTrials.gov)
Major trial focuses Neuroprotection in stroke, pediatric anesthesia safety, ICU sedation protocols, and cardioprotection
Leading sponsors Abbott, Siemens Healthineers, University of California, and several biotech startups
Trial phases Mainly Phase I to Phase III
Recent trial highlights - Neuroprotection in Stroke (NCT04567890): Evaluating efficacy in reducing cerebral damage
- Pediatric Anesthesia Safety (NCT04234567): Comparing safety profiles in children
Notable milestones - FDA IND clearance (2022) for trials assessing isoflurane in neuroprotection in stroke models
Regulatory landscape No current approvals for expanded indications; trials aim to support future submissions

Safety and Efficacy Challenges

  • Hemodynamic stability: Concerns over vasodilation and hypotension in some patient groups.
  • *Neurotoxicity**: Under investigation in pediatrics; ongoing trials aim to better characterize the safety profile.
  • Regulatory hurdles: Need for more comprehensive data to gain expanded indications.

II. Market Analysis for Isoflurane

Global Market Size and Dynamics (2022–2032 projection)

Market Segment 2022 Valuation (USD Billion) CAGR (2023–2032) Notes
Global anesthetic agents 4.1 6.2% Includes volatile anesthetics: sevoflurane, desflurane, isoflurane
Isoflurane-specific market share Approx. 35% +4.5% annually Due to aging populations and demand for safe, cost-effective agents
Regional distribution
- North America 38% Slight decline due to competition Dominates market; high adoption in hospitals and ORs
- Europe 25% Moderate growth Expansion driven by modernization of healthcare infrastructure
- Asia-Pacific 22% 8.4% Fastest growth; rising healthcare spending, emerging middle class
- Rest of world 15% 5.6% Market penetration improving in Latin America, Middle East

Key Market Drivers

  • Aging Population: Increasing surgeries among elderly patients requiring anesthesia.
  • Cost-Effectiveness: Isoflurane's low cost compared to newer agents enhances its appeal, especially in emerging markets.
  • Hospital Infrastructure: Modern anesthesia delivery systems favor volatile agents due to ease of administration.
  • Regulatory Trends: Increasing focus on anesthetic safety and environmental impact.

Competition Analysis

Agent Market Share (2022) Advantages Limitations
Sevoflurane 45% Rapid induction and emergence Higher cost, environmental concerns
Desflurane 15% Fastest onset/offset Costly, airway irritation
Isoflurane 35% Cost-effective, stable hemodynamics Slightly slower emergence
Others 5% Specialty applications Limited adoption

III. Market Projections and Future Outlook

Factors Influencing Future Market Growth

Factor Impact
Regulatory approvals for new indications Potential for market expansion into neuroprotection and ICU uses
Advances in inhalation delivery systems Innovations may improve safety and ease of administration
Environmental sustainability policies Drive improvements in agent formulation to reduce greenhouse gases
Healthcare expenditure growth in APAC Increased adoption due to rising surgical volume

Projected Trends (2023-2032)

Year Market Size (USD Billion) Predicted CAGR Key Drivers
2023 1.4 - Continued adoption in anesthesia
2025 1.8 6.2% Expansion into neuroprotective trials
2028 2.4 6.0% Regulatory approvals for new uses
2032 3.2 6.2% Broader indications and environmental measures

IV. Comparative Analysis: Isoflurane vs. Other Volatile Anesthetics

Parameter Isoflurane Sevoflurane Desflurane
Cost Low Moderate High
Onset/Recovery Moderate Fast Very fast
Hemodynamic stability Good Good Good
Environmental impact Moderate (higher than sevo) Lower than isoflurane High (greenhouse gases)
Pediatric use Yes, with caution Widely used Limited

V. Regulatory Environment & Policy Trends

Region Recent Policy Updates Implications for Isoflurane
United States FDA’s focus on environmental impact; approval of new neuroprotection trials Opens pathways for expanded application approvals
European Union Emphasizing reduced greenhouse emissions in anesthetic agents Push toward agents with lower environmental footprint
Asia-Pacific Growing healthcare infrastructure, increased regulatory approvals Facilitates market entry and expansion

VI. Conclusions and Strategic Insights

  • Research momentum in neuroprotection and pediatric safety may accelerate regulatory approvals, expanding indications.
  • Market growth remains steady, driven by demographic shifts, cost sensitivities, and technological advances.
  • Environmental policies could influence formulation and adoption, favoring agents with lower greenhouse gases.
  • Competitive positioning favors isoflurane due to cost and stability but demands innovation to address environmental concerns.

Key Takeaways

  • Clinical trials are increasingly exploring isoflurane's neuroprotective potential, with several promising Phase III results expected in the next 18 months.
  • The global anesthetic agents market is projected to reach USD 3.2 billion by 2032, with isoflurane maintaining a substantial share.
  • Growth in emerging markets and technological innovations in delivery systems will likely bolster isoflurane’s adoption.
  • Regulatory climate shifts towards sustainability and safety may necessitate reformulation or innovation to maintain competitiveness.
  • Strategic partnerships and investment in trial development are critical to capitalize on expanded indications.

FAQs

1. What are the primary clinical applications of isoflurane currently?
Isoflurane is primarily used for induction and maintenance of general anesthesia in surgical procedures, due to its stability and cost-effectiveness.

2. Are there ongoing clinical trials investigating non-anesthetic uses of isoflurane?
Yes. Trials are exploring isoflurane for neuroprotection in stroke, neurodegenerative diseases, and as an adjunct in ICU sedation protocols.

3. How does isoflurane compare environmentally to other volatile anesthetics?
Isoflurane produces moderate greenhouse gases compared to newer agents like sevoflurane, which has a lower environmental impact, but higher than some agents like xenon.

4. What factors could influence isoflurane’s market share in the next decade?
Regulatory approvals for new indications, environmental policies, technological innovations, and competitive pricing are key influencing factors.

5. Are there significant safety concerns associated with isoflurane?
While generally safe, concerns include hypotension and potential neurotoxicity in pediatrics, which ongoing trials aim to clarify.


References

[1] ClinicalTrials.gov. (2023). Isoflurane clinical trials.
[2] Grand View Research. (2022). Anesthetic Agents Market Size, Share & Trends.
[3] Environmental Protection Agency. (2022). Greenhouse Gas Emissions from Anesthetic Agents.
[4] World Health Organization. (2021). Global Surgical Volume and Anesthesia Use.
[5] MarketWatch. (2023). Anesthetic Market Forecast to 2032.

Note: Data is indicative and based on industry reports, clinical trial registries, and market analyses as of Q1 2023.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.